CA2837341C - Method of determining vasoreactivity using inhaled nitric oxide - Google Patents

Method of determining vasoreactivity using inhaled nitric oxide Download PDF

Info

Publication number
CA2837341C
CA2837341C CA2837341A CA2837341A CA2837341C CA 2837341 C CA2837341 C CA 2837341C CA 2837341 A CA2837341 A CA 2837341A CA 2837341 A CA2837341 A CA 2837341A CA 2837341 C CA2837341 C CA 2837341C
Authority
CA
Canada
Prior art keywords
patient
vasoreactivity
determining
nitric oxide
inhaled nitric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2837341A
Other languages
English (en)
French (fr)
Other versions
CA2837341A1 (en
Inventor
Tammy WATTS
Robert F. Roscigno
David H. Fine
Lewis J. Rubin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vero Biotech Inc
Original Assignee
Vero Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vero Biotech Inc filed Critical Vero Biotech Inc
Publication of CA2837341A1 publication Critical patent/CA2837341A1/en
Application granted granted Critical
Publication of CA2837341C publication Critical patent/CA2837341C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
    • A61B5/026—Measuring blood flow
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
    • A61M16/10—Preparation of respiratory gases or vapours
    • A61M16/12—Preparation of respiratory gases or vapours by mixing different gases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Medical Informatics (AREA)
  • Anesthesiology (AREA)
  • Physiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Steroid Compounds (AREA)
CA2837341A 2011-05-27 2012-05-24 Method of determining vasoreactivity using inhaled nitric oxide Active CA2837341C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161490929P 2011-05-27 2011-05-27
US61/490,929 2011-05-27
PCT/US2012/039401 WO2012166534A1 (en) 2011-05-27 2012-05-24 Method of determining vasoreactivity using inhaled nitric oxide

Publications (2)

Publication Number Publication Date
CA2837341A1 CA2837341A1 (en) 2012-12-06
CA2837341C true CA2837341C (en) 2021-10-19

Family

ID=47259769

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2837341A Active CA2837341C (en) 2011-05-27 2012-05-24 Method of determining vasoreactivity using inhaled nitric oxide

Country Status (6)

Country Link
US (1) US11154210B2 (enExample)
EP (1) EP2713723B1 (enExample)
JP (3) JP2014527025A (enExample)
AU (1) AU2012262534B2 (enExample)
CA (1) CA2837341C (enExample)
WO (1) WO2012166534A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7560076B2 (en) 2004-08-18 2009-07-14 Geno Llc Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
US7618594B2 (en) 2004-08-18 2009-11-17 Geno Llc Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
WO2009097343A1 (en) 2008-01-28 2009-08-06 Geno Llc Conversion of nitrogen dioxide (no2) to nitric oxide (no)
US8607785B2 (en) 2008-08-21 2013-12-17 Geno Llc Systems and devices for generating nitric oxide
JP5878866B2 (ja) 2009-06-22 2016-03-08 ゲノ エルエルシー 一酸化窒素治療
JP2014527025A (ja) 2011-05-27 2014-10-09 ゲノ エルエルシー 吸入用一酸化窒素を用いて血管反応性を決定する方法
EP4024719A1 (en) 2014-04-15 2022-07-06 CommScope Technologies LLC Wideband remote unit for distributed antenna system
US10398820B2 (en) * 2016-02-12 2019-09-03 Mallinckrodt Hospital Products IP Limited Use and monitoring of inhaled nitric oxide with left ventricular assist devices
EP4095094A1 (en) 2017-02-27 2022-11-30 Third Pole, Inc. Systems and methods for ambulatory generation of nitric oxide
MX2020010523A (es) 2017-02-27 2021-02-09 Third Pole Inc Sistemas y metodos para generar oxido nitrico.
BR112019016708B1 (pt) 2017-02-27 2024-01-30 Third Pole, Inc Sistemas de geração de óxido nítrico
US11672938B1 (en) 2018-07-18 2023-06-13 Vero Biotech LLC Start-up protocols for nitric oxide delivery device
US20210386944A1 (en) * 2018-10-12 2021-12-16 Sanotize Research Development Corp. Gas-evolving compositions and container and delivery systems
CN114269685A (zh) 2019-05-15 2022-04-01 第三极股份有限公司 用于一氧化氮生成的电极
WO2020232419A1 (en) 2019-05-15 2020-11-19 Third Pole, Inc. Systems and methods for generating nitric oxide
WO2021142472A1 (en) 2020-01-11 2021-07-15 Third Pole, Inc. Systems and methods for nitric oxide generation with humidity control
EP4167920A4 (en) 2020-06-18 2024-06-12 Third Pole, Inc. Systems and methods for preventing and treating infections with nitric oxide
JP2024534608A (ja) 2021-09-23 2024-09-20 サード ポール，インコーポレイテッド 一酸化窒素を送達するシステム及び方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6758214B2 (en) 2000-01-28 2004-07-06 Cyterra Corporation Simple nitric oxide generator for ambulatory and/or bedside inhaled no treatment
EP1429829B1 (en) 2001-09-05 2013-11-27 Geno LLC Nitric oxide generation
US7560076B2 (en) 2004-08-18 2009-07-14 Geno Llc Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
US7618594B2 (en) 2004-08-18 2009-11-17 Geno Llc Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
EP1819340A2 (en) 2004-12-08 2007-08-22 Biomarin Pharmaceutical Inc. Methods and compositions for the treatment of pulmonary hypertension of the newborn
WO2007087575A2 (en) * 2006-01-24 2007-08-02 University Of Chicago Compositions and methods for treating pulmonary hypertension
CA2681308C (en) 2007-03-23 2015-11-24 Geno Llc Conversion of nitrogen dioxide (no2) to nitric oxide (no)
WO2009097343A1 (en) 2008-01-28 2009-08-06 Geno Llc Conversion of nitrogen dioxide (no2) to nitric oxide (no)
EP2306814B1 (en) 2008-07-24 2013-11-27 Geno LLC Methods for diagnosing and treating a heart condition in a patient
US8701657B2 (en) 2008-08-21 2014-04-22 Geno Llc Systems for generating nitric oxide
US8607785B2 (en) 2008-08-21 2013-12-17 Geno Llc Systems and devices for generating nitric oxide
US10780241B2 (en) 2008-08-21 2020-09-22 Vero Biotech LLC Devices and methods for minimizing and treating high-altitude sickness
US10960168B2 (en) 2008-08-21 2021-03-30 Vero Biotech LLC Delivery of high concentration nitric oxide
EP2362810A4 (en) 2008-09-22 2013-09-11 Geno Llc CONVERSION OF NITROGEN DIOXIDE (NO2) TO NITROGEN MONOXIDE (NO)
JP5878866B2 (ja) 2009-06-22 2016-03-08 ゲノ エルエルシー 一酸化窒素治療
JP2011010865A (ja) * 2009-06-30 2011-01-20 Ikaria Holdings Inc 肺高血圧の臨床的または超音波心臓検査上の証拠を伴う低酸素性呼吸器不全に罹った満期産およびほぼ満期産の新生児を治療する方法
JP5995724B2 (ja) * 2009-11-20 2016-09-21 ゲノ エルエルシー 一酸化窒素送達システム
US20120093948A1 (en) * 2009-11-20 2012-04-19 Fine David H Nitric Oxide Treatments
AU2011245474B2 (en) 2010-04-26 2016-01-07 VERO Biotech LLC. Nitrosyl special connector
AU2011245476B2 (en) 2010-04-26 2016-05-12 VERO Biotech LLC. Delivery of ultra pure nitric oxide (NO)
USD688352S1 (en) 2010-04-27 2013-08-20 Geno Llc Female gas connector
USD679366S1 (en) 2010-04-27 2013-04-02 Geno Llc Male gas connector
AU2011336358B2 (en) * 2010-12-03 2016-09-29 VERO Biotech LLC. Nitric oxide treatments
CA2833914A1 (en) * 2011-05-10 2012-11-15 Universite Laval Methods for the treatment and diagnostic of pulmonary arterial hypertension
JP2014527025A (ja) 2011-05-27 2014-10-09 ゲノ エルエルシー 吸入用一酸化窒素を用いて血管反応性を決定する方法
EP4180078A1 (en) 2014-10-20 2023-05-17 VERO Biotech LLC Nitrogen dioxide storage cassette

Also Published As

Publication number Publication date
JP2017165731A (ja) 2017-09-21
JP2019131556A (ja) 2019-08-08
EP2713723A4 (en) 2015-03-25
WO2012166534A1 (en) 2012-12-06
CA2837341A1 (en) 2012-12-06
US20130309328A1 (en) 2013-11-21
AU2012262534A1 (en) 2013-12-12
JP2014527025A (ja) 2014-10-09
US11154210B2 (en) 2021-10-26
EP2713723A1 (en) 2014-04-09
AU2012262534B2 (en) 2016-06-02
EP2713723B1 (en) 2018-09-12

Similar Documents

Publication Publication Date Title
CA2837341C (en) Method of determining vasoreactivity using inhaled nitric oxide
AU2018201942B2 (en) Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
IN2014KN00996A (enExample)
MX2017014338A (es) Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina.
WO2012081898A3 (ko) 위암의 예후 예측용 마커 및 이를 이용하는 위암의 예후 예측 방법
HK1198869A1 (en) Combination treatments for hepatitis c
CA3266267A1 (en) Use of inhaled nitric oxide for the improvement of right and/or left ventricular function
EP4512470A3 (en) Methods of treating heart failure with cardiac sarcomere activators
WO2012158437A3 (en) Cannula apparatus and ventricular assist systems using the cannula apparatus
PH12013500411A1 (en) Treatment of myocardial infarction using tgf - beta antagonists
TN2016000083A1 (en) Methods and tools relating to the administration of contrast medium
WO2012058585A3 (en) Treatment of heart failure with natriuretic peptides
WO2011127019A3 (en) Methods for treating respiratory viral infection
MX354981B (es) Medicamento para tratamiento terapeutico y/o mejoramiento de sepsis.
MX2013007055A (es) Derivados de sanglifehrina y metodos para su produccion.
WO2015066664A3 (en) Compositions and methods for administration of an enzyme to a subject's airway
WO2012040444A3 (en) Treatment of patients with incipient alzheimer's disease
WO2012146736A8 (en) Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium salts in the treatment of cardiovascular disease
UA64830U (ru) Способ лечения больных гастроезофагеальной рефлюксной болезнью в сочетании с хроническим обструктивным заболеванием легких
EP4410368A3 (en) Promoting lung growth
UA53602U (ru) Способ возмещения кровопотери при политравме в условиях догоспитального этапа
UA62741U (ru) Способ профилактики респираторных осложнений после операции на легких и плевре с разными видами торакопластики
UA69733U (ru) Способ диагностики диастолической дисфункции левого желудочка у больных с неосложненной гипертонической болезнью
Reynolds Cardiac resynchronization for heart failure: Its time has come
UA71756U (ru) Способ лечения деструктивного туберкулеза легких

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20161219